Cell Therapeutics (NASDAQ: CTIC) hat auch angekündigt, die Rechte an einem Krebsmedikament von Chorma Therapeutics zu kaufen.
Cell Therapeutics Inc. (NASDAQ: CTIC) shares jumped more than 10% to trade at $0.32 today, shortly after the company announced that it has bought exclusive rights to an anti-cancer drug from Chorma Therapeutics Ltd. Cell Therapeutics said that the rights pertain to marketing and co-development of Chroma’s tosedostat. The company further stated that this drug “has demonstrated significant anti-tumor responses in blood related cancers and solid tumors in … trials.”
Quelle: www.beaconequity.com/...-cancer-drug-2011-03-16/#ixzz1Grh7vuzv